Emmaus

Emmaus Life Sciences Provides Interim Shipment Data

Retrieved on: 
Monday, April 3, 2023

TORRANCE, Calif., April 3, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle ell disease treatment, announced today preliminary results for the 3 months ended March 31, 2023.

Key Points: 
  • TORRANCE, Calif., April 3, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle ell disease treatment, announced today preliminary results for the 3 months ended March 31, 2023.
  • "We look forward to reporting our complete interim financial results on our Forms 10-Q for the first quarter as soon as possible.
  • In the meantime, we are pleased to provide information regarding our interim volume of shipments," said Dr. Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer.
  • The shipment volume trend has been as follows:

Emmaus Life Sciences Reports Financial Results for the Six Months Ended June 30, 2021

Retrieved on: 
Thursday, September 2, 2021

TORRANCE, Calif., Sept. 2, 2021 /PRNewswire/ --Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced financial results for the six months ended June 30, 2021.

Key Points: 
  • TORRANCE, Calif., Sept. 2, 2021 /PRNewswire/ --Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced financial results for the six months ended June 30, 2021.
  • Financial Results for the Six Months Ended June 30, 2021
    Net revenues for the six months ended June 30, 2021 increased by 5% to $11.8 million compared to the same period in 2020.
  • The operating loss for the half of 2021 was attributable to the increase in operating expenses as noted above.
  • Cash and cash equivalents were $1.7 million as of June 30, 2021 compared to $2.5 million as of December 31, 2020.

Texas Adds Endari® to Latest Preferred Drug List

Retrieved on: 
Monday, August 2, 2021

According to the THHS website, preferred drugs are medications recommended by the Texas Drug Utilization Review Board for their efficaciousness, clinical significance, cost effectiveness, and safety.

Key Points: 
  • According to the THHS website, preferred drugs are medications recommended by the Texas Drug Utilization Review Board for their efficaciousness, clinical significance, cost effectiveness, and safety.
  • The Texas Medicaid Formulary contains all products, including those on the preferred drug list, available to people enrolled in Medicaid.
  • With this recent revision, Texas joins many other states in improving access to Endari for the treatment of sickle cell disease in Medicaid patients.
  • "We greatly appreciate that Texas Health and Human Services has eliminated the prior authorization criteria for Endari.

Emmaus Life Sciences Announces Submission of Endari® Marketing Authorization Application in Kuwait

Retrieved on: 
Thursday, July 15, 2021

TORRANCE, Calif., July 15, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA),a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today the submission of its application for Marketing Authorization (MA) for Endari to the Kuwait Drug and Food Control (KDFC).

Key Points: 
  • TORRANCE, Calif., July 15, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA),a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today the submission of its application for Marketing Authorization (MA) for Endari to the Kuwait Drug and Food Control (KDFC).
  • This is the first step in the registration of Endari by the KDFC, which is responsible for the registration of pharmaceutical products in Kuwait.
  • "We are pleased to announce the submission of our marketing authorization application to the Kuwaiti authorities.
  • Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories.

Emmaus Life Sciences Reports Annual Financial Results for 2020 and Provides Updated Business Review

Retrieved on: 
Tuesday, May 4, 2021

Limited interim study results were encouraging, suggesting that Endari may be effective in slowing and reversing the progression of diverticulosis.

Key Points: 
  • Limited interim study results were encouraging, suggesting that Endari may be effective in slowing and reversing the progression of diverticulosis.
  • Progress continues at the manufacturing facility in Ube, Japan purchased by a 40% owned investee of Emmaus in December of 2019.
  • To meet the long-term potential demand for PGLG, Emmaus, its partners and contractors are in the process of obtaining regulatory approvals and recertifications of the facility.
  • In addition, on November 10, 2020 the company announced its submission of a temporary license application in Bahrain for Endari.

Emmaus Life Sciences Announces Collaboration with Kainos Medicine for Preclinical Development of IRAK4 Inhibitor as Potential Anti-Cancer Drug

Retrieved on: 
Tuesday, March 2, 2021

In a related development, the companies also entered into a letter of intent regarding possible future joint development of small molecule therapeutics and other pharmaceutical assets.

Key Points: 
  • In a related development, the companies also entered into a letter of intent regarding possible future joint development of small molecule therapeutics and other pharmaceutical assets.
  • Kainos will receive $500,000 in cash and $500,000 in shares of Emmaus common stock in consideration for entering into the agreement.
  • "Emmaus is pleased to partner with Kainos to further advance the research and development activity of KM10544," said Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer of Emmaus.
  • Kainos receives specialized counsel on product selection, evaluation and external licensing deals from advisory boards and business development consultants who have skills and significant experience in global drug development.

Emmaus Life Sciences Submits Temporary License Application in Bahrain for Endari®

Retrieved on: 
Tuesday, November 10, 2020

TORRANCE, Calif., Nov. 10, 2020 /PRNewswire/ --Emmaus Life Sciences, Inc. (OTC: EMMA),a leader in the treatment of sickle cell disease, announced today that it has submitted a temporary license application for Endari to the National Health Regulatory Authority in the Kingdom of Bahrain.

Key Points: 
  • TORRANCE, Calif., Nov. 10, 2020 /PRNewswire/ --Emmaus Life Sciences, Inc. (OTC: EMMA),a leader in the treatment of sickle cell disease, announced today that it has submitted a temporary license application for Endari to the National Health Regulatory Authority in the Kingdom of Bahrain.
  • Upon approval of the temporary license application, Emmaus will apply for MAA, which typically takes twelve months.
  • The temporary license will allow Endari to be prescribed in Bahrain pending MAA.
  • "This submission of a temporary license application for Endari is another important step in our commitment to serve sickle cell disease patients in the MENA region," said Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer of Emmaus.

Emmaus Life Sciences Provides Additional Operational and OTC Markets Updates

Retrieved on: 
Friday, July 31, 2020

Sales Updates Outside the U.S.

Key Points: 
  • Sales Updates Outside the U.S.
    Emmaus continues to make progress in developing markets for Endari in the Middle East and North Africa (MENA) region.
  • These developments will accelerate the companys efforts to reach the estimated 100,000 potentially treatable sickle cell disease patients in the MENA region.
  • Prescriptions from Emmaus main specialty pharmacy partners increased in the second quarter as compared to the first quarter of 2020.
  • Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories.

Emmaus Life Sciences Accelerates Middle East and North Africa (MENA) Growth Strategy with Opening of its Dubai Office

Retrieved on: 
Thursday, July 23, 2020

TORRANCE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today the opening of its regional office in Dubai.

Key Points: 
  • TORRANCE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today the opening of its regional office in Dubai.
  • The Dubai office will be utilized to enhance Emmaus relationships with clinicians and patient groups at major hospitals and other government-sponsored health care facilities in communities throughout the Middle East and North Africa (MENA) region.
  • As product registration and marketing authorization are obtained, deploy local medical science liaisons (MSLs) and account managers to call on local hospitals and clinics.
  • Such forward-looking statements speak only as of the date they are made, and Emmaus assumes no duty to update them, except as may be required by law.

Emmaus Life Sciences Announces Engagement of Partner International to Lead Out-Licensing of Endari® for Diverticulosis

Retrieved on: 
Thursday, July 16, 2020

Diverticulosis is an often asymptomatic gastrointestinal (GI) condition affecting a large segment of the adult populations in the U.S. and elsewhere.

Key Points: 
  • Diverticulosis is an often asymptomatic gastrointestinal (GI) condition affecting a large segment of the adult populations in the U.S. and elsewhere.
  • Joanne Ball-Gautschi, CEO and President of Partner International commented, Our firm is extremely proud to represent Emmaus in identifying potential partners for its PGLG oral powder as a treatment for diverticulosis.
  • Partner International is a leading business development group in the life sciences industry, offering a full range of corporate development services, including partnering, licensing, and M&A.
  • Partner International has operations in Switzerland, Canada, United States, and Australia, as well as strategic associates in 26 countries globally.